Executive interview – Kazia Therapeutics

Executive interview – Kazia Therapeutics

Associated equity: Kazia Therapeutics

Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.

Kazia Therapeutics — 9 videos in collection

In this video, Kazia’s CEO, Dr James Garner, explains the background to this interesting product which has a novel brain penetrating action which potentially could give it a unique role in the chronic treatment of glioblastoma. He discusses the latest trial data and the further development of the product in 2020.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free